TELA Bio (TELA) Osake Kurssi

TELA Bio Inc is primarily active in the healthcare and medical device industry.

The main competitors of TELA Bio Inc in the market include companies such as Johnson & Johnson, Medtronic, Integra LifeSciences, and Baxter International. These companies also operate in the medical technology industry and offer products and solutions that are similar to TELA Bio Inc. Competing against these established players, TELA Bio Inc strives to differentiate itself through innovative product offerings, advanced technologies, and a focus on meeting the specific needs of patients and healthcare providers.

TELA Bio Inc is a company specializing in surgical reconstruction and healing technologies. Founded in 2012, TELA Bio has quickly made a name for itself in the medical industry. Inspired by the groundbreaking research of scientists and surgeons, TELA Bio develops innovative products aimed at improving patient outcomes in soft tissue reconstruction. With a strong focus on bioengineering and advanced materials, TELA Bio's solutions are designed to address various surgical challenges effectively. TELA Bio Inc's dedication to innovation and commitment to patients has positioned them as a leading player in the field, providing healthcare professionals with cutting-edge solutions for better patient care.

TELA Bio Inc has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) in February 2020, raising approximately $51 million. This marked a major achievement for TELA Bio Inc in terms of gaining access to public capital markets. Additionally, the company has received regulatory clearance for its OviTex portfolio of surgical implants, including OviTex PRS and OviTex RSM, which are used in various soft tissue reconstruction procedures. TELA Bio Inc has also experienced notable success in expanding its market presence and commercializing its products across the United States. These achievements demonstrate TELA Bio Inc's strong growth and determination in the medical technology field.

TELA Bio Inc is primarily present in the United States.

TELA Bio Inc represents a strong commitment to improving patient outcomes and quality of life through its innovative surgical reconstruction solutions. The company's corporate philosophy revolves around fostering partnerships with healthcare professionals and delivering unmatched value to both patients and providers. TELA Bio focuses on developing and commercializing advanced biomaterials and surgical implants, enabling surgeons to address complex soft tissue challenges effectively. With a dedication to research, development, and technological advancements, TELA Bio strives to create transformative medical solutions that support optimal patient healing and recovery.

11 analyytikkoa arvioi tällä hetkellä TELA Bio-osaketta: 9 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat TELA Bio-yhtiöltä 79,64 M USD liikevaihtoa ja −0,59 USD osakekohtaista tulosta.

TELA Bio Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla TELA Bio-osake noteerataan hintaan 1,00 EUR (1,12 USD).

TELA Bio-osake (TELA) on listattuna 1 pörssissä, muun muassa: NASDAQ (TELA).

The company TELA Bio Inc is a leading company in the field of biological tissue reconstruction and manufactures a wide range of innovative products. TELA Bio's business model is based on the development, manufacturing, and marketing of high-quality biotissue products used in the restoration and regeneration of tissues in the human body. TELA Bio's products include biological structures made from specially treated animal and/or plant skin. These structures are ideal for reconstructing damaged tissues such as muscle and fiber tissues and are used in various medical fields. The products are predominantly used in plastic and reconstructive surgery, general surgery, gynecology, and thoracic surgery. TELA Bio offers its customers a variety of products tailored to their specific requirements and needs. These include biological mesh structures that can be used in abdominal wall reconstruction or breast tissue restoration, as well as long-term replacement structures for connective tissue, muscles, or tendons. Additionally, TELA Bio also provides custom-made products specifically tailored to the individual needs of the patient. Another important aspect of TELA Bio's business model is its collaboration with doctors, medical professionals, and scientists. The company continually invests in research and development to improve and enhance its products. Through close collaboration with medical professionals, TELA Bio ensures that its products meet the highest quality and safety standards. TELA Bio also follows a clear growth strategy by continuously expanding its customer base and expanding its product range. The company has expanded its presence in the global market and distributes its products in Europe, Asia, and South America. As TELA Bio operates in a growing market, there are numerous opportunities for future growth and further expansion. Overall, TELA Bio's business model is characterized by a high level of innovation, close collaboration with medical professionals, and a clear growth strategy. Through the development and manufacturing of high-quality biotissue products, the company makes an important contribution to improving medical care and enhancing the quality of life for patients worldwide. Answer: TELA Bio Inc is a leading company in the field of biological tissue reconstruction. They develop, manufacture, and market high-quality biotissue products used in the restoration and regeneration of human tissues. These products are used in various medical fields including plastic and reconstructive surgery, general surgery, gynecology, and thoracic surgery. TELA Bio offers a wide range of products tailored to the specific needs of their customers. They collaborate with doctors, medical professionals, and scientists to ensure the highest quality and safety standards. TELA Bio also follows a clear growth strategy and has expanded its presence in the global market. They contribute to improving medical care and enhancing the quality of life for patients worldwide.

odotettu liikevaihto TELA Bio on 79,64 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto TELA Bio on −30,38 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

TELA Bio:n hinta-voitto-suhde (P/E) on tällä hetkellä −1,91. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan TELA Bio-osakkeen arvostusta.

TELA Bio:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,73. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii TELA Bio-osakkeen arvostuskennuslukuna.

TELA Bio:n Eulpool-laatuscore on 3/10.

TELA Bio:n ISIN on US8723811084. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

TELA Bio:n WKN on A2PUP9. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

TELA Bio:n ticker on TELA. Tämä pörssinoteeraus käytetään TELA Bio-osakkeiden kauppaan pörssissä.